


[View this email in your browser](#)



# REPRIEVE Insights

Quarterly Updates on Milestones and Discoveries



## April 2024 Table of Contents

- [What's New From REPRIEVE?](#)
- [Two New Manuscripts Hot off the Press!](#)
- [New! Recommendations for the Use of Statin Therapy\\_\(based on REPRIEVE data!\) in People with HIV](#)
- [Help Us Spread the Word!](#)
- [REPRIEVE @ CROI 2024](#)
- [Stay Tuned: REPRIEVE Request for Proposals](#)
- [REPRIEVE In the News](#)
- [We Need Your Help to Share Impacts of REPRIEVE!](#)
- [REPRIEVE Results Sharing](#)

---

## What's New From REPRIEVE?



**It has been an exciting spring for REPRIEVE!** Since our last newsletter, the results of the REPRIEVE mechanistic substudy were published in JAMA Cardiology, REPRIEVE Team members presented 6 abstracts of new data at CROI 2024, and the DHHS/AHA/ACC/HIVMA announced new guidance for statin use in HIV, integrating the results of REPRIEVE into clinical guidelines. **These exciting updates and more are featured in our REPRIEVE Insights newsletter for this quarter.**

Sincerely,  
REPRIEVE Leadership

**Two New Manuscripts Hot off the Press!**

# Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV

## Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial


Michael T. Lu, MD, MPH; Heather Ribaldo, PhD; Borek Foldyna, MD; Markella V. Zanni, MD; Thomas Mayrhofer, PhD; Julia Karady, MD, PhD; Jana Taron, MD; Kathleen V. Fitch, MSN; Sara McCallum, MPH; Tricia H. Burdo, PhD; Kayla Paradis, MBA; Sandeep S. Hedgire, MD; Nandini M. Meyersohn, MD; Christopher DeFilippi, MD; Carlos D. Malvestutto, MD, MPH; Audra Sturniolo, MS; Marissa Diggs, BA; Sue Siminski, MBA; Gerald S. Bloomfield, MD; Beverly Alston-Smith, MD; Patrice Desvigne-Nickens, MD; Edgar T. Overton, MD; Judith S. Currier, MD; Judith A. Aberg, MD; Carl J. Fichtenbaum, MD; Udo Hoffmann, MD, MPH; Pamela S. Douglas, MD; Steven K. Grinspoon, MD; for the REPRIEVE Trial Writing Group

Journal of the American Heart Association

### ORIGINAL RESEARCH

---

# Polygenic Scores and Preclinical Cardiovascular Disease in Individuals With HIV: Insights From the REPRIEVE Trial

Roger S. Zou , MD, PhD; Yunfeng Ruan , PhD; Buu Truong , MD; Romit Bhattacharya , MD; Michael T. Lu , MD, MPH; Júlia Karády , MD, PhD; Rachel Bernardo , BS; Phoebe Finneran, BS; Whitney Hornsby , PhD; Kathleen V. Fitch , MSN; Heather J. Ribaldo , PhD; Markella V. Zanni , MD; Pamela S. Douglas , MD; Steven K. Grinspoon, MD, PhD; Aniruddh P. Patel , MD\*; Pradeep Natarajan , MD, MMSc\*

These manuscripts--published in JAMA Cardiology and JAHA--share important new insights into why pitavastatin reduced heart disease events in REPRIEVE and a new method for estimating heart disease risk for PWH. Visit our [publications page](#) to read the full publications and plain language summaries.

## **New! Recommendations for the Use of Statin Therapy (based on REPRIEVE data!) in People with HIV are Now Available!**

**Updated:** February 27, 2024

**Reviewed:** February 27, 2024

### **Recommendations for the Use of Statin Therapy as Primary Prevention of Atherosclerotic Cardiovascular Disease in People with HIV**

Statement released: February 27, 2024

These recommendations of the U.S. Department of Health and Human Services (HHS) Panel for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (the Panel) have been developed in collaboration with representatives from the American College of Cardiology (ACC), American Heart Association (AHA), and the HIV Medicine Association (HIVMA). The following recommendations and supporting text have then been reviewed and endorsed by these respective organizations. These recommendations inform the use of statin therapy in primary prevention of atherosclerotic cardiovascular disease (ASCVD) in people with HIV receiving care in the United States.

## **Help Us Spread the Word!**

During this phase of REPRIEVE, the **Clinical Coordinating Center** is focused on dedicated dissemination and education efforts to **support the interpretation of REPRIEVE findings and to support the adoption and implementation of guidelines in practice**. One part of this effort is this digital quarterly newsletter, *REPRIEVE Insights: Quarterly Updates on Milestones and Discoveries*.

**Anyone** interested in staying up-to-date with REPRIEVE activities and future publications can sign up for this newsletter. To this end,



please distribute the signup link (below) and/or [click here](#) to download and distribute a flyer with a QR code to ensure that as many people as possible can stay in touch with REPRIEVE.

[REPRIEVE Insights Newsletter Sign Up Form](#)

*Please share this with anyone who might be interested in receiving information about REPRIEVE. THANK YOU!!!*

## REPRIEVE @ CROI 2024



In March, the REPRIEVE Team presented exciting new data at CROI 2024 in Denver, Colorado! REPRIEVE had 2 oral presentations and 4 poster presentations, and REPRIEVE Team members Steve Grinspoon and Markella Zanni delivered talks during a symposium titled “Follow Your Heart: Managing Cardiovascular Disease Risk in HIV.”

We've included a few photos of REPRIEVE Team members from the conference, and a complete list of the REPRIEVE activities that took place at CROI is available on our [website!](#)



## Stay Tuned: REPRIEVE Request for Proposals

Stay tuned for an announcement from REPRIEVE about a request for proposals (RFP). More information will be shared on our [website](#) in early May. Check back soon!

## REPRIEVE In the News

**MEDPAGETODAY™**

Perspectives > Second Opinions

### A Closer Look at the New Statin Therapy Guidelines for Patients With HIV

— Clinicians can use these recommendations to navigate primary CVD prevention efforts

by Kathleen V. Fitch, MSN, Marissa Diggs, and Steven Grinspoon, MD April 2, 2024

Earlier this month, members of the REPRIEVE team discussed the new statin therapy guidelines for people with HIV in MedPage Today. Click [here](#) to read the full piece!



## We Need Your Help to Share Impacts of REPRIEVE!

Results from REPRIEVE are making an impact across the globe, from changing guidelines to changing the care of people living with HIV. If you have a story about how results from REPRIEVE have changed your care or clinical practice we want to hear from you! Please reach out to Katie Fitch ([kfitch@mgh.harvard.edu](mailto:kfitch@mgh.harvard.edu)) or Marissa Diggs ([mdiggs@mgh.harvard.edu](mailto:mdiggs@mgh.harvard.edu)) at the REPRIEVE Clinical Coordinating Center (CCC).



## REPRIEVE Results Sharing

The REPRIEVE Trial website has a central webpage on which various REPRIEVE results materials are posted. The materials include:

- Graphical abstract of trial results
- Statin guidance for PWH
- Slide templates for presentations to providers
- Slide templates for presentations to the community
- Participant FAQs, and more!

If you are interesting sharing results from REPRIEVE in your local area or want to learn more this webpage is a great place to visit! Go to: <https://www.reprivevtrial.org/learnmore/results-of-the-reprivev-trial/>.

*For future reference, all newsletters are available on the [REPRIEVE Website](#)*

## Our sponsors and collaborators



Like, comment, share, and repost!

***REPRIEVE Trial Clinical Coordinating Center***

Massachusetts General Hospital  
50 Staniford St, Suite 750  
Boston, MA USA 02114

---



---

This email was sent to [mdiggs@mgh.harvard.edu](mailto:mdiggs@mgh.harvard.edu)  
[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)  
Massachusetts General Hospital · 5 Longfellow Place · Boston, MA 02214 · USA

